SCHEMBL17926576

SCHEMBL17926576

FCCn1ncc2c(Cl)nc(Cl)nc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 4/20 0.39
TRAP1 Q12931 4/20 0.39
HSP90AB1 P08238 1/20 0.39
PDE2A O00408 9/20 0.38
HSP90B1 P14625 1/20 0.35
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C19 P33261 1/20 0.33
KMT2A Q03164 1/20 0.33
CNR2 P34972 1/20 0.32
GAA P10253 1/20 0.32
KDM4E B2RXH2 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
ATM Q13315 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2786539 0.85 PDE1A (0.42) HSP90AA1TRAP1HSP90AB1PDE2AHSP90B1
SCHEMBL7919917 0.85 CYP1A2 (0.39) HSP90AA1TRAP1HSP90AB1PDE2AHSP90B1
SCHEMBL25876223 0.83 PDE2A (0.40) PDE2ACYP1A2CYP3A4CYP2D6CYP2C19
SCHEMBL2804826 0.82 PDE2A (0.39) PDE2A
SCHEMBL30095837 0.82 PDE2A (0.39) PDE2A
SCHEMBL30748233 0.81
SCHEMBL2189832 0.81 ADORA3 (0.43) HSP90AA1TRAP1HSP90AB1PDE2AHSP90B1
SCHEMBL23579830 0.80 HSP90AA1 (0.40) HSP90AA1TRAP1HSP90AB1PDE2AHSP90B1
SCHEMBL4451017 0.79 ALDH1A1 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19KMT2A
SCHEMBL175230 0.77 ADORA2A (0.47) CYP1A2CYP3A4CYP2D6CNR2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
EP-4115882-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING The General Hospital Corporation (US) 2023-01-11 EP disclosed
EP-4115882-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING The General Hospital Corporation (US) 2023-01-11 EP disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed
EP-3244891-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING The General Hospital Corporation (US) 2017-11-22 EP disclosed
WO-2016115434-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING THE GENERAL HOSPITAL CORPORATION (US) 2016-07-21 WO disclosed
WO-2016115434-A1 COMPOUNDS FOR IMPROVING MRNA SPLICING THE GENERAL HOSPITAL CORPORATION (US) 2016-07-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HSP90AA1 3561/4885TRAP1 1844/4885HSP90AB1 3353/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HSP90AA1 3561/4885TRAP1 1844/4885HSP90AB1 3353/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HSP90AA1 3561/4885TRAP1 1844/4885HSP90AB1 3353/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 HSP90AA1 3561/4885TRAP1 1844/4885HSP90AB1 3353/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 HSP90AA1 3561/4885TRAP1 1844/4885HSP90AB1 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.